Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.
Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 3, 2 and 1 respectively.
Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.
Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 3, 2 and 1 respectively.
Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Vasomotor Symptoms of Menopause (Hot Flashes) - Overview
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vasomotor Symptoms of Menopause (Hot Flashes) - Companies Involved in Therapeutics Development
AstraZeneca Plc
EndoCeutics Inc
MenoGeniX Inc
Mithra Pharmaceuticals SA
N4 Pharma Plc
Ogeda SA
Pherin Pharmaceuticals Inc
TherapeuticsMD Inc
Vasomotor Symptoms of Menopause (Hot Flashes) - Drug Profiles
(estradiol + progesterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(estradiol acetate + progesterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene hydrochloride + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fezolinetant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MNGX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paroxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pavinetant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PH-80HF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects
Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products
Vasomotor Symptoms of Menopause (Hot Flashes) - Product Development Milestones
Featured News & Press Releases
Oct 13, 2017: Mithra Announces Completion of Recruitment in Donesta Phase II Study
Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-001HR at NAMS 2017
May 15, 2017: Millendo Therapeutics Announces MLE4901 Data Presentations at European Congress of Endocrinology and Congress of the European Menopause and Andropause Society
Apr 03, 2017: TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017
Jan 04, 2017: Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes
Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364
Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR
Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
Oct 13, 2015: TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate
Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes
Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection
Oct 18, 2013: TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Vasomotor Symptoms of Menopause (Hot Flashes) - Overview
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vasomotor Symptoms of Menopause (Hot Flashes) - Companies Involved in Therapeutics Development
AstraZeneca Plc
EndoCeutics Inc
MenoGeniX Inc
Mithra Pharmaceuticals SA
N4 Pharma Plc
Ogeda SA
Pherin Pharmaceuticals Inc
TherapeuticsMD Inc
Vasomotor Symptoms of Menopause (Hot Flashes) - Drug Profiles
(estradiol + progesterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(estradiol acetate + progesterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene hydrochloride + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fezolinetant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBN-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MNGX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
paroxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pavinetant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PH-80HF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects
Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products
Vasomotor Symptoms of Menopause (Hot Flashes) - Product Development Milestones
Featured News & Press Releases
Oct 13, 2017: Mithra Announces Completion of Recruitment in Donesta Phase II Study
Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-001HR at NAMS 2017
May 15, 2017: Millendo Therapeutics Announces MLE4901 Data Presentations at European Congress of Endocrinology and Congress of the European Menopause and Andropause Society
Apr 03, 2017: TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO 2017
Jan 04, 2017: Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes
Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364
Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR
Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
Oct 13, 2015: TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate
Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes
Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection
Oct 18, 2013: TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by AstraZeneca Plc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by EndoCeutics Inc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by MenoGeniX Inc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Mithra Pharmaceuticals SA, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by N4 Pharma Plc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Ogeda SA, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Pherin Pharmaceuticals Inc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by TherapeuticsMD Inc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products, H2 2017
Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by AstraZeneca Plc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by EndoCeutics Inc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by MenoGeniX Inc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Mithra Pharmaceuticals SA, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by N4 Pharma Plc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Ogeda SA, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Pherin Pharmaceuticals Inc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by TherapeuticsMD Inc, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products, H2 2017
LIST OF FIGURES
Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
AstraZeneca Plc
EndoCeutics Inc
MenoGeniX Inc
Mithra Pharmaceuticals SA
N4 Pharma Plc
Ogeda SA
Pherin Pharmaceuticals Inc
TherapeuticsMD Inc
Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
AstraZeneca Plc
EndoCeutics Inc
MenoGeniX Inc
Mithra Pharmaceuticals SA
N4 Pharma Plc
Ogeda SA
Pherin Pharmaceuticals Inc
TherapeuticsMD Inc
